Table 1. Studies describing the use of high-dose intravenous methylprednisolone in allergic bronchopulmonary aspergillosis
Fist author [ref.]PatientsAge yearsM/FRisk factorMean serum IgE IU·mL−1Methylprednisolone doseSteroid durationOutcomesSide-effects
Thomson [9]46.075 (1.7–8.2)3/1CF2950.520 mg·kg−1 every 4 weeks4 years3 out of 4 patients had clinical stabilisationHypertension and hyperglycaemia in one patient each
Cohen-Cymberknoh [10]917.1 (7–36)4/5CF54210–15 mg·kg−1 (max 1 g) every 4 weeks6–10 monthsSignificant improvement in FEV1 and decreased IgE in all casesWeight gain and psychiatric disorder in one patient each
Thomas [11]1111/0CF917820 mg·kg−1 for 3 days followed by 10 mg·kg−1 for 3 days6 daysClinical stabilisation
Skov [12]2519.9 (10–34)16/9CFNA15 mg·kg−13–7 monthsClinical stabilisation; reduction in the number of exacerbationsMinimal side-effects
  • Data are presented as n or mean (range), unless otherwise stated. M: males; F: females; CF: cystic fibrosis; NA: not available; FEV1: forced expiratory volume in 1 s.